The Niigata University study published in Science Advances (2026) presents a multi-level investigation linking lower plasma copper to autism spectrum disorder (ASD) symptom severity and reduced white-matter volume. Human data were observational, drawn from plasma trace-element panels and MRI scans in individuals with ASD versus controls; no randomized controlled trial design was used and exact sample sizes remain unreported in the coverage, limiting generalizability. Mouse experiments provided causal evidence: developmental copper deficiency impaired oligodendrocyte maturation, reduced myelination, and produced social and repetitive behavioral phenotypes via elevated BNIP3-mediated mitophagy and suppressed mTOR signaling. This pathway integrates mitochondrial quality control with glial development, an angle rarely emphasized in mainstream autism-metabolism reporting. Earlier work, such as the 2019 meta-analysis in Molecular Psychiatry (n>1,000 across 15 studies) documenting consistent mitochondrial electron-transport-chain abnormalities in ASD, supplies convergent context that the Niigata team does not fully exploit. Likewise, a 2022 Nature Neuroscience paper on oligodendrocyte–neuron metabolic coupling in social circuits offers a missing bridge between the observed myelin deficits and core social symptoms. The original MedicalXpress summary correctly cautions against copper supplementation yet underplays two critical limitations: plasma copper is a poor proxy for brain copper status, and ASD heterogeneity means any single trace-element signal will apply only to a biologically defined subgroup. The mechanistic insight—that copper deficiency can remotely tune mTOR-dependent oligodendrocyte development through mitophagy—suggests future stratification studies combining plasma metals, white-matter imaging, and mitochondrial biomarkers could refine prognosis far beyond current behavioral diagnostics.